Almac Pharma Services Capabilities Update November 2026: Bioavailability And Solubility
Bioavailability (%F) is the fraction of an administered drug dose that reaches the systemic circulation unchanged and is available to produce a therapeutic effect. It reflects the body's exposure to the drug and is commonly assessed from drug concentrations in blood. In general, a drug must be in its molecular form and in solution at the absorption site before it can enter the bloodstream by passive diffusion or active transport. Nanomedicines may be absorbed through alternative pathways. Un-ionised drugs typically diffuse across lipid membranes more readily than ionised drugs.
Improving bioavailability generally requires increasing solubility, permeability, or both. This presentation explains how the Biopharmaceutics Classification System (BCS) is used to predict oral drug absorption and identify appropriate bioenhancement strategies.
The most common strategy is to improve drug solubility or dissolution rate through salt selection, particle-size reduction, or amorphous formulations. Particle size can be reduced by techniques such as jet milling, microfluidisation, or wet bead milling. Amorphous systems present the drug in a non-crystalline state and typically provide faster dissolution and greater solubility than crystalline material. This presentation will show how spray-dried amorphous dispersions, hot-melt extrusion, and lipid-based dispersions or solutions can improve bioavailability. Other approaches, including co-precipitation and ion exchange, will also be considered.
Improving permeability is more challenging because it depends largely on the molecule's ability to cross cell membranes and enter the bloodstream. Once the transport mechanism is understood, targeted strategies may be possible; for example, transporter-mediated efflux may be reduced by saturating P-glycoprotein (P-gp). Molecular approaches include prodrug design, lipidisation, and hydrophobic conjugation. Drug-product strategies may include permeation enhancers, enteric coatings, lipid nanoparticles, or self-emulsifying drug delivery systems (SEDDS, SMEDDS, or SNEDDS).
Biorelevant solubility and dissolution testing are critical for selecting and optimising an appropriate bioenhancement strategy. The presentation will also cover in vitro permeability assessment tools used to support formulation development and optimise drug bioavailability.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.